Navigation Links
CED 1902 isolated pre-amplifier from Cambridge Electronic Design Limited

ProductsCED 1902 isolated pre-amplifier from Cambridge Electronic Design Limited
Company Cambridge Electronic Design Limited
Item CED 1902 isolated pre-amplifier
Price $2,310.00
Description Versatile, modular, computer controlled pre-amplifier suitable for a broad range of applications. Includes an isolated electrode input for recording physiological signal such as ECG, EMG, SCR and EEG, and a transducer input for use with a wide range of bridge and other transducers. Additional options include a stimulus artefact clamp to avoid saturation when using high intensity magnetic stimulation and a buffer for multi-channel common-reference studies. Available as single, dual or quad channel units. Multiple unts can be controlled from a single serial line.
Info Cambridge Electronic Design Limited
Science Park
Milton Road
Cambridge
UK
CB4 0FE
Customer Service: +44 (0)1223 420166
Fax Number: +44 (0)1223 420488
Web Site: http://www.ced.co.uk
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Power1401 laboratory interface from Cambridge Electronic Design Limited
2. Spike2 version 6 software from Cambridge Electronic Design Limited
3. Signal software from Cambridge Electronic Design Limited
4. OEM-EPC Electronic Pressure Control from Parker Hannifin Corporation
5. Peptide Design and Custom Synthesis from Global Peptide Services, LLC.
6. Corning Resuable Pp Vial Rack, Non-Sterile, 50 Positions, Self Locking Design from Sigma-Aldrich
7. Mouse Anti-Ubiquitin, Multi Monoclonal Antibody, Unconjugated, Clone FK2 from Assay Designs/Stressgen Bioreagents
8. Rabbit Anti-Human ErbB-2, phospho (Tyr1248) Polyclonal Antibody, Unconjugated from Assay Designs/Stressgen Bioreagents
9. Flashlight-Trigger Solution from Assay Designs/Stressgen Bioreagents
10. Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
11. Acridinium C2 NHS Ester from Assay Designs/Stressgen Bioreagents
Wheat Germ Agglutinin (WGA) PS SPA Imaging Bead from GE Healthcare, formerly Amersham Biosciences
...s to 1 outflow Single-cell and patch delivery Re...illisecond) solution change Very small dead volum...Solid construction 360, 250 and 100 micron delive...manipulator Available in 4, 8, and 16 channels. S...
Sf21 Frozen Cells (Grace's Media) from Invitrogen
... most comprehensive, cost-effective solution to yo...orated unprecedented quality into both our product...etection chemistries and antibodies that have been...des our competitively priced accessories that can ...
Biology Products:
(Date:12/1/2009)...Particularly in Alzheimer,s disease, nerve cell de...w therapeutic options may possibly be derived from...m. These findings have been published in the curre...nce . Until only a few years ago, neurogenesis th...d to be impossible in the adult brain. The textboo...
(Date:12/1/2009)...Yehezkel Ben-Ari, winner of the 2009 Inserm Grand ...d its commitment to paying tribute to outstanding,...s. By honouring talents, Inserm intends to,demons...ved in today,s biological, medical and,health res...nd women who carry out and,drive this research ea...
(Date:12/1/2009)...In a world first, a Monash University-led internat...y to boost the output of the next generation of so... collaboration with colleagues from the universiti... tandem dye-sensitised solar cells with a three-fo...ed with previously reported tandem dye-sensitised ...
Breaking Biology News(10 mins):New source discovered for the generation of nerve cells in the brain 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Innovation puts next-generation solar cells on the horizon 2Cardium Announces Plans to File FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Gel for Diabetic Pressure and Venous 14682 1Cardium Announces Plans to File FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Gel for Diabetic Pressure and Venous 14682 2Cardium Announces Plans to File FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Gel for Diabetic Pressure and Venous 14682 3Cardium Announces Plans to File FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Gel for Diabetic Pressure and Venous 14682 4China National Medicines Corporation Issues Milestone Purchase Order for 12 000 STA Systems 5913 1China National Medicines Corporation Issues Milestone Purchase Order for 12 000 STA Systems 5913 2China National Medicines Corporation Issues Milestone Purchase Order for 12 000 STA Systems 5913 3China National Medicines Corporation Issues Milestone Purchase Order for 12 000 STA Systems 5913 4Global Atrial Fibrillation Device Market to Grow by Almost 10 25 Through 2013 5910 1Global Atrial Fibrillation Device Market to Grow by Almost 10 25 Through 2013 5910 2Global Atrial Fibrillation Device Market to Grow by Almost 10 25 Through 2013 5910 3
...at help shape our understanding of how tool use ha...red evidence that chimpanzees, at least under some...and using tools to hunt mammalian prey. The work, ...nd Paco Bertolani of the University of Cambridge, ...on February 22nd. , Chimpanzees are well known for...
...ersion of a computer chip, a team led by Johns Hop...y related to the mating habits of yeast cells. ,...line Publication of the journal Nature, shed new l...m one another and from the environment through a p...hen impaired, can lead to cancer or other illnesse...
...tion and large scale culture of stem cells for pot...n cell biology. In an upcoming PLoS ONE paper, res...y, France) report, on the basis of experimental ob... cell identity in culture may strongly depend on t...s are in line with the currently emerging view tha...
Other Biology News:Chimpanzees found to use tools to hunt mammalian prey 2Microfluidic chip helps solve cellular mating puzzle 2Microfluidic chip helps solve cellular mating puzzle 3
(Date:12/1/2009)..., British Columbia, Dec. 1 /PRNewswire-FirstCall/ ... of The Dow Chemical Company (NYSE: DOW ), and A...ing of a research and commercial license option ag...ith access to Agrisoma,s proprietary Engineered Tr... major food crops, and on a non-exclusive basis, i...
(Date:12/1/2009)...ing provider of products for biological sample col...l Services will offer Oragene•DNA sample coll... and genotyping service. , ...tek , a leading provider of products for biologica...Pharmaceutical Services will offer Oragene•...
(Date:12/1/2009)... 34-year veteran of the high-technology industry, ...s development and intellectual property management...ace. The company also plans to invest in promisin...or. , Monterey, CA (PRWEB...r veteran of the high-technology industry, has for...
(Date:11/30/2009)...Newswire/ -- The Michael J. Fox Foundation for Par...ion in total awards to six research teams working ... for Parkinson,s disease. The funding was awarded ...Parkinson,s Disease program, made possible by fun...neuroscience-based biotechnology company. ,, T...
Breaking Biology Technology:Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3